Annie K Baa

DM, Medical Oncology(AIIMS, Delhi) MD,Medicine (VMMC& SJH) MBBS (St. Johns’s, Bangalore)

[Annie K Baa @annie_baa]

@DrGPrakash @RanjitKSMD @doctorpemm @TilakTVSVGK What a shot sir 👌 clean basket !👏👏

[Dr Amol Akhade @SuyogCancer]

Carboplatin for early stage TNBC.
All trials in one slide . It
should be given to those who don't have acess to IO .
Those who can receive IO , further question is, if it can reduce anthracycline use . Good discussion @SABCSSanAntonio #SABCS2025 @OncoAlert

[Oncology Brothers @OncBrothers]

I worry that the majority of that benefit is being driven by BRCA and PLAB2. Is this going to be your 1L for all HRRm? @neerajaiims @DrRanaMcKay @dr_yakupergun

PARPi have a good amount of side effects with very little benefit with certain HRR deficiencies. Love this slide by @AlanBryce9

[Dr Amol Akhade @SuyogCancer]

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to:
🔹 Colorectal: +103%
🔹 Pancreatic: +100%
🔹 Esophageal: +86%
🔹 Liver: +81%
🌍 Biggest increases in Asia & Africa
💡 Call to action: Early detection, access, equity.
Time for GI oncologist to collaborate and fight against this problem
#ESMOGI25 #GlobalOncology #GIcancer #CancerInequity @myESMO @NiuSanford
@MyriamChalabi @OncBrothers @OncoAlert @medicalwatchBC

[Jose Fernando Moura, PhD @FernandoOnco]

Some studies shows how we can reduce costs based on biomarkers
SHORT-HER 9 weeks of trastuzumab is ✅ based TILS 20% or more
@TILsWorkGroup @OncoAlert #oncoalertAF @JAMAOnc⤵️
https://t.co/VlXgw6Iohh

[Yakup Ergün @dr_yakupergun]

#ESMOGI25 Starts tomorrow

TALENTACE: TACE + Atezo + Bev vs TACE Alone in uHCC

TACE-PFS: 11.3 vs 7 mo (HR: 0.71)

PFS (RECIST v1.1): 10.3 vs 6.3 mo

Grade 3-5 TRAEs: 63.8% vs 42.2%

(EMERALD-1➡️15.0 vs 8.2 mo, HR:0.77)

(LEAP-012: 14.6 vs 10.0 mo, HR:0.66)

[Dr Amol Akhade @SuyogCancer]

KEYNOTE-689 Update at #AACR25
Neoadjuvant + adjuvant #pembrolizumab in resectable LA-HNSCC
✅ EFS HR: 0.73 (95% CI 0.58–0.92)
✅ Median EFS: 51.8 mo vs 30.4 mo
✅ CPS ≥10 subgroup: HR 0.66 (95% CI 0.49–0.88)
✅ 2-yr EFS: 75% vs 62%
✅ Early & sustained KM curve separation
✅ Benefit seen across PD-L1 strata and tumor stages
⚡ Hypopharynx subgroup showed no clear benefit (tiny n).
⚡ OS still awaited.
New perioperative IO standard incoming?
@OncoAlert
@Larvol @AACR @OncLive @OncBrothers

[Dr Amol Akhade @SuyogCancer]

When you treat metastatic CRPC in elderly person, polypharmacy and drug to drug interactions needs to noted . These are some common drug interactions with Abiraterone and Enzalutamide. Useful for clinical practice @OncoAlert @medicalwatchBC @OncBrothers @dr_yakupergun

[Annie K Baa @annie_baa]

@SauraVermaMD @ConquerCancerFd @GeneseeqInc @DrDanBreadner @DrSymYoung Congratulations sir 😊

[soria @jsoriamd]

Carcinoma of Unknown Primary: Cancer without a past
🧬 Early dissemination
🛡️Immune editing of the primary
🧪CK20+, CDX2+, SATB2+ → treat colon-like
🧭Let biology, not anatomy, guide therapy
Not a diagnostic failure — a metastatic strategy.
https://t.co/fTKLByy1RF
#ASCO25 #CUP #CancerBiology

[Paolo Tarantino @PTarantinoMD]

The #TolAlgorithm for treating HR+/HER2- MBC in (the first half of) 2025

@stolaney1 #ESMOBreast25 #esmoambassadors

[Paolo Tarantino @PTarantinoMD]

Real world data suggest that chemo (cape, eribulin, taxanes) outperforms a second topo1 ADC after progression on T-DXd. Key question to address in breast oncology (and across oncology fields!). #ESMOBreast25 #esmoambassadors

[Annie K Baa @annie_baa]

@Amolpatel_dr @AACR Congratulations sir 😊

[Dr Amol Akhade @SuyogCancer]

CDK4/6 Rechallenge Trials: What Works? What Fails?
📢 published in @JCO_ASCO: PALMIRA Trial
❌ Rechallenging palbociclib post-progression shows no PFS benefit
In contrast:
🟢 MAINTAIN → Switching to ribociclib improves PFS
🟢 postMONARCH → Switching to abemaciclib improves PFS
Key takeaway: Switching CDK4/6 inhibitors post-progression offers better outcomes than rechallenging with the same agent. What do u do ? Switch or Rechallenge?
@ASCO @OncoAlert @dr_yakupergun @OncBrothers @drsarahsam

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Our correspondence in @TheLancet on the TRANSMET trial.
@annie_baa @Amolpatel_dr @DrJasminPorwall https://t.co/cxc37hH6EL

[Dr Amol Akhade @SuyogCancer]

Uncommon EGFR mutations in NSCLC often fly under the radar.
This is one slide showing the first-line data for uncommon EGFR mutations — from 4 trials - ACHILLES, UNICORN, KCSG-lu15-09 , and CHRYSALIS-2 ( cohort C ) #oncotwitter #uncomonEGFR #LCSM @OncoAlert @OncBrothers

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Doxorubicin–Trabectedin in Leiomyosarcoma | New England Journal of Medicine
@NEJM
Sharing our correspondence for the LMS 04 article @annie_baa https://t.co/n8WVVQvGAI

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Advances in alveolar soft part sarcoma treatment in the era of immunotherapy - ESMO Rare Cancers
@myESMO @samdoc_mamc https://t.co/KzNyycmgmn

[Paolo Tarantino @PTarantinoMD]

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by @DrHBurstein & @curijoey. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

[akhilrk1989 @akhilrk1989]

🚨Thrilled to share our Burkitt lymphoma/leukemia study in @BloodCancerJnl. Massive effort(n=265) from @HCC_HemeCancer. MTX & EPOCH protocols equally effective overall, but MTX outperforms in CSF+ & BM+ cases. Valuable insights for treatment decisions! https://t.co/vg8633gLc2